Cardiac prevention guidelines

John W. McEvoy; Roger S. Blumenthal; Erin D. Michos

doi:10.1007/978-3-319-15961-4_2

Cardiac prevention guidelines

John W. McEvoy, Roger S. Blumenthal, Erin D. Michos

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

In this chapter, we summarize a number of recently released guideline documents for the prevention of cardiovascular disease. Specifically, guidelines for the assessment of cardiovascular risk, the treatment of high cholesterol, the treatment of obesity, optimizing diet and healthy lifestyle habits, and the treatment of hypertension are discussed. Particular focus is given to new developments in these guidelines, pharmacologic considerations related to the guidelines, as well as positive and negative attributes of the recommendations. A thorough understanding of these recent guidelines, including their strengths and weaknesses, is critical in order to deliver the most up-to-date evidence-based cardiovascular care.

Original language	English (US)
Title of host publication	Pathophysiology and Pharmacotherapy of Cardiovascular Disease
Publisher	Springer International Publishing
Pages	21-36
Number of pages	16
ISBN (Electronic)	9783319159614
ISBN (Print)	9783319159607
DOIs	https://doi.org/10.1007/978-3-319-15961-4_2
State	Published - Jan 1 2015

Keywords

Cardiac risk
Guidelines
Hypercholesterolemia
Hypertension
Obesity
Preventive cardiology

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
General Medicine

Access to Document

10.1007/978-3-319-15961-4_2

Cite this

@inbook{ae8da9626cce41e8aa760e2d6494fff4,

title = "Cardiac prevention guidelines",

abstract = "In this chapter, we summarize a number of recently released guideline documents for the prevention of cardiovascular disease. Specifically, guidelines for the assessment of cardiovascular risk, the treatment of high cholesterol, the treatment of obesity, optimizing diet and healthy lifestyle habits, and the treatment of hypertension are discussed. Particular focus is given to new developments in these guidelines, pharmacologic considerations related to the guidelines, as well as positive and negative attributes of the recommendations. A thorough understanding of these recent guidelines, including their strengths and weaknesses, is critical in order to deliver the most up-to-date evidence-based cardiovascular care.",

keywords = "Cardiac risk, Guidelines, Hypercholesterolemia, Hypertension, Obesity, Preventive cardiology",

author = "McEvoy, {John W.} and Blumenthal, {Roger S.} and Michos, {Erin D.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-15961-4_2",

language = "English (US)",

isbn = "9783319159607",

pages = "21--36",

booktitle = "Pathophysiology and Pharmacotherapy of Cardiovascular Disease",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Cardiac prevention guidelines

AU - McEvoy, John W.

AU - Blumenthal, Roger S.

AU - Michos, Erin D.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In this chapter, we summarize a number of recently released guideline documents for the prevention of cardiovascular disease. Specifically, guidelines for the assessment of cardiovascular risk, the treatment of high cholesterol, the treatment of obesity, optimizing diet and healthy lifestyle habits, and the treatment of hypertension are discussed. Particular focus is given to new developments in these guidelines, pharmacologic considerations related to the guidelines, as well as positive and negative attributes of the recommendations. A thorough understanding of these recent guidelines, including their strengths and weaknesses, is critical in order to deliver the most up-to-date evidence-based cardiovascular care.

AB - In this chapter, we summarize a number of recently released guideline documents for the prevention of cardiovascular disease. Specifically, guidelines for the assessment of cardiovascular risk, the treatment of high cholesterol, the treatment of obesity, optimizing diet and healthy lifestyle habits, and the treatment of hypertension are discussed. Particular focus is given to new developments in these guidelines, pharmacologic considerations related to the guidelines, as well as positive and negative attributes of the recommendations. A thorough understanding of these recent guidelines, including their strengths and weaknesses, is critical in order to deliver the most up-to-date evidence-based cardiovascular care.

KW - Cardiac risk

KW - Guidelines

KW - Hypercholesterolemia

KW - Hypertension

KW - Obesity

KW - Preventive cardiology

UR - http://www.scopus.com/inward/record.url?scp=84944128652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944128652&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15961-4_2

DO - 10.1007/978-3-319-15961-4_2

M3 - Chapter

AN - SCOPUS:84944128652

SN - 9783319159607

SP - 21

EP - 36

BT - Pathophysiology and Pharmacotherapy of Cardiovascular Disease

PB - Springer International Publishing

ER -

Cardiac prevention guidelines

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this